The nation of Zimbabwe has turned down a substantial US health deal valued at $367m (272 million pounds) spanning five years because of the United States' insistence on confidential data.
The decision came to light after a government memo dated December was leaked, which showed Head of State Emmerson Mnangagwa felt the arrangement was "lopsided".
An official representative has since stated that the US was seeking health data for scientific study and profit but refused to share the resulting advantages from any future medical innovations.
"We are forced to start the challenging and unfortunate process of ending our health aid in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont publicly.
The US Embassy indicated the US had donated more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has called for further negotiations to find a deal agreeable to all parties so the country's vital HIV treatment initiative can proceed.
Broader Implications
This rejection comes after a comparable case in Kenya, where a high court blocked a related deal with the US after concerns were filed about the security of citizens' medical information.
After resuming office last year, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
The agency had managed aid for the US government, but Trump stated its expenditure was "inefficient" and his administration was seeking direct bilateral agreements to boost openness and responsibility.
Based on reports, Sixteen African countries have to date signed similar health pacts, constituting over $18.3bn in new funding.
Specifics of the Declined Deal
The money for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this partnership might have yielded extraordinary benefits for the people of Zimbabwe, especially the 1.2 million currently on HIV treatment via US-supported initiatives," Tremont added.
However, official spokesman Nick Mangwana said the arrangement was "unfair".
"The proposal required Zimbabwe to provide its biological resources and data for a long time, without any corresponding promise of benefiting from any scientific breakthroughs – such as vaccines, diagnostics, or treatments – that could result from that provided information," his statement read.
"In essence, our country would supply the raw materials for medical research without any certainty that the end products would be accessible to our population should a new health crisis emerge."
National Interest and Global Health
He also noted that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral deals were disrupting frameworks already set up through the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing framework designed to deal with future pandemics.
"This mechanism is designed to guarantee that when a nation provides its information, the benefits – including medicines and cures – are shared equitably, not commercialised solely by those with the capability to develop them."
The government's concerns regarding the US deal "are not meant as opposition to America," Mangwana stressed.
"We welcome ongoing dialogue with our US partners on how future co-operation might be structured in a manner that respects the independence and interests of each country."
Medical Community Response
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it understood the official position, but recommended that negotiations must proceed considering a large portion of the nation's Aids initiatives depended on foreign aid.
"In cases where technical issues exist, such as those involving information security or implementation frameworks, these can frequently be resolved through detailed discussion and mutually agreed protections," it said.
The halted deal underscores the ongoing tensions between receiving crucial foreign assistance and protecting a country's data in an increasingly data-driven world.